Llorca P M, Lançon C, Reine G
CH Sainte-Marie, Clermont-Ferrand.
Encephale. 1997 Nov-Dec;23(6):431-6.
Depression and mood disorders are frequently associated. They can be described as a part of schizophrenic symptomatology, observed as post-psychotic depression, be a part of a schizoaffective disorder or be a consequence of neuroleptic treatment. Suicide is the main risk of evolution in young schizophrenics and is often associated to depression. Despite methodological difficulties, a few studies demonstrate the efficacy of clozapine, one of the first atypical antipsychotic, in the treatment of depressive symptomatology in schizophrenics and schizoaffectives. This action remains controversial in the treatment of post-psychotic depression. This drug also contribute to reduce suicidality in a sample of chronic schizophrenics in an open study. This action has to be considered when we evaluate the risk-benefit of the prescription of clozapine.
抑郁症和情绪障碍常常相关。它们可被描述为精神分裂症症状学的一部分,表现为精神病后抑郁,或是分裂情感性障碍的一部分,亦或是抗精神病药物治疗的后果。自杀是年轻精神分裂症患者病情发展的主要风险,且常与抑郁相关。尽管存在方法学上的困难,但一些研究表明,氯氮平(首批非典型抗精神病药物之一)在治疗精神分裂症和分裂情感性障碍患者的抑郁症状方面具有疗效。在治疗精神病后抑郁方面,这一作用仍存在争议。在一项开放性研究中,该药物在慢性精神分裂症患者样本中也有助于降低自杀倾向。在评估氯氮平处方的风险效益时,必须考虑这一作用。